Summary
PacingCure has developed BradyTx-01: a novel gene therapy medicinal product (GTMP) to cure life-threatening cardiac pacing dysfunctions by reprogramming cardiomyocytes into pacemaker cells. BradyTx-01 is based on a novel method to optimally control transcription factor overexpression through adeno-associated Virus (AAV) mediated gene transfer. The “biological pacemaker” that is created (1) improves cardiac function, (2) responds to metabolic demand, (3) can be delivered using minimally invasive techniques and (4) potentially lasts a lifetime.
In the TRACTION project, PacingCure – together with AUMC – will further optimize AAV-mediated transcription vector gene therapy for pacemaker applications, validating the novel AAV vector technology in mice, pigs and non-human primates. Subsequently, a large-scale manufacturing process will be designed to release the materials that will be used for validating and demonstrating long-term safety and efficacy in porcine studies, thereby establishing preclinical proof-of-concept of BradyTx-01.
In parallel, we will validate and optimize the technology-product-market fit of BradyTx-01, and the evolving value propositions will be tested and optimized with relevant stakeholders. We will define the optimal regulatory strategies, perform health technology assessments and develop the optimal business strategy, thereby setting the stage for effective clinical and commercial development of BradyTx-01.
Within the TRACTION project, we will take the next steps in our development, while also establishing the optimal strategy for our trajectory towards the clinical stage and commercialization of BradyTx-01. The TRACTION project will thus facilitate the complete transition of PacingCure into a fully operational company with an attractive and investment-ready business proposition.
In the TRACTION project, PacingCure – together with AUMC – will further optimize AAV-mediated transcription vector gene therapy for pacemaker applications, validating the novel AAV vector technology in mice, pigs and non-human primates. Subsequently, a large-scale manufacturing process will be designed to release the materials that will be used for validating and demonstrating long-term safety and efficacy in porcine studies, thereby establishing preclinical proof-of-concept of BradyTx-01.
In parallel, we will validate and optimize the technology-product-market fit of BradyTx-01, and the evolving value propositions will be tested and optimized with relevant stakeholders. We will define the optimal regulatory strategies, perform health technology assessments and develop the optimal business strategy, thereby setting the stage for effective clinical and commercial development of BradyTx-01.
Within the TRACTION project, we will take the next steps in our development, while also establishing the optimal strategy for our trajectory towards the clinical stage and commercialization of BradyTx-01. The TRACTION project will thus facilitate the complete transition of PacingCure into a fully operational company with an attractive and investment-ready business proposition.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/101099608 |
| Start date: | 01-01-2023 |
| End date: | 31-12-2025 |
| Total budget - Public funding: | 2 499 968,75 Euro - 2 499 968,00 Euro |
Cordis data
Original description
PacingCure has developed BradyTx-01: a novel gene therapy medicinal product (GTMP) to cure life-threatening cardiac pacing dysfunctions by reprogramming cardiomyocytes into pacemaker cells. BradyTx-01 is based on a novel method to optimally control transcription factor overexpression through adeno-associated Virus (AAV) mediated gene transfer. The “biological pacemaker” that is created (1) improves cardiac function, (2) responds to metabolic demand, (3) can be delivered using minimally invasive techniques and (4) potentially lasts a lifetime.In the TRACTION project, PacingCure – together with AUMC – will further optimize AAV-mediated transcription vector gene therapy for pacemaker applications, validating the novel AAV vector technology in mice, pigs and non-human primates. Subsequently, a large-scale manufacturing process will be designed to release the materials that will be used for validating and demonstrating long-term safety and efficacy in porcine studies, thereby establishing preclinical proof-of-concept of BradyTx-01.
In parallel, we will validate and optimize the technology-product-market fit of BradyTx-01, and the evolving value propositions will be tested and optimized with relevant stakeholders. We will define the optimal regulatory strategies, perform health technology assessments and develop the optimal business strategy, thereby setting the stage for effective clinical and commercial development of BradyTx-01.
Within the TRACTION project, we will take the next steps in our development, while also establishing the optimal strategy for our trajectory towards the clinical stage and commercialization of BradyTx-01. The TRACTION project will thus facilitate the complete transition of PacingCure into a fully operational company with an attractive and investment-ready business proposition.
Status
SIGNEDCall topic
HORIZON-EIC-2022-TRANSITIONOPEN-01Update Date
31-07-2023
Images
No images available.
Geographical location(s)
